German firm Bayer is bringing to India a drug to treat chronic kidney disease associated with diabetes patients and costing one-fifteenth of the price in the US.
Brand named Kerendia (Finerenone) will cost Rs 97.5 per day. “The recent Indian Chronic Kidney Disease (ICKD) study identifies diabetes as the leading cause of chronic kidney disease and end-stage kidney disease in India. Over 40% of all patients with diabetes will develop chronic kidney disease. Seventy-four million people suffer from diabetes in India and this figure is likely to increase to ninety-three million by 2030, making it an epidemic,” Bayer said.
After China, India